Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 67.21% is 17% below its 5-year average of 81.28%, near the high end of its 5-year range (-72.47%–94.29%).
9.40% above its 12-month average of 61.43%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 15.84%.
GROSS MARGIN
67.21%
GROSS MARGIN AVG TTM
61.43%
GROSS MARGIN AVG 3Y
80.80%
GROSS MARGIN AVG 5Y
81.28%
GROSS MARGIN AVG 10Y
63.24%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+9.40%
CURRENT VS 3Y AVG
-16.82%
CURRENT VS 5Y AVG
-17.31%
CURRENT VS 10Y AVG
+6.28%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 853 covered companies
CURRENT VS SECTOR MEDIAN
+62.42%
vs the sector median at left
Jaguar Health, Inc.
Market Cap
$2.47M
Gross Margin
67.21%
TTM Avg
61.43%
3Y Avg
80.80%
5Y Avg
81.28%
Market Cap
$2.52M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.54M
Gross Margin
23.21%
TTM Avg
29.65%
3Y Avg
45.21%
5Y Avg
30.14%
Market Cap
$2.39M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.35M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.37M
Gross Margin
80.40%
TTM Avg
59.71%
3Y Avg
-452.13%
5Y Avg
-301.42%
Market Cap
$2.31M
Gross Margin
63.43%
TTM Avg
61.72%
3Y Avg
62.82%
5Y Avg
60.98%
Market Cap
$2.21M
Gross Margin
-628.02%
TTM Avg
-265.21%
3Y Avg
-2905.33%
5Y Avg
-2576.02%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jaguar Health, Inc. (JAGX) | $2.47M | 67.21% | 61.43% | 80.80% | 81.28% |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.52M | 0.00% | 0.00% | 0.00% | 0.00% |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.54M | 23.21% | 29.65% | 45.21% | 30.14% |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.39M | 0.00% | 0.00% | 0.00% | 0.00% |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.35M | 0.00% | 0.00% | 0.00% | 0.00% |
| Onconetix, Inc. (ONCO)vs › | $2.37M | 80.40% | 59.71% | -452.13% | -301.42% |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.31M | 63.43% | 61.72% | 62.82% | 60.98% |
| Nuwellis, Inc. (NUWE)vs › | $2.61M | 69.69% | 64.31% | 60.13% | 58.62% |
| GeoVax Labs, Inc. (GOVX)vs › | $2.21M | -628.02% | -265.21% | -2905.33% | -2576.02% |
| Vivos Therapeutics, Inc. (VVOS)vs › | $2.16M | 59.72% | 60.22% | 60.72% | 66.21% |
Gross Margin
67.2%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 15.84% |
| 2026-03-31 | 94.29% |
| 2025-12-31 | 31.99% |
| 2025-09-30 | 82.74% |
| 2025-06-30 | 82.31% |
| 2025-03-31 | 76.74% |
| 2024-12-31 | 84.13% |
| 2024-09-30 | 82.59% |
| 2024-06-30 | 84.31% |
| 2024-03-31 | 81.71% |
| 2023-12-31 | 70.13% |
| 2023-09-30 | 81.73% |
| 2023-06-30 | 81.65% |
| 2023-03-31 | 82.51% |
| 2022-12-31 | 84.82% |
| 2022-09-30 | 80.54% |
| 2022-06-30 | 84.39% |
| 2022-03-31 | 82.67% |
| 2021-12-31 | 77.45% |
| 2021-09-30 | 2.06% |
| 2021-06-30 | -72.47% |
| 2021-03-31 | 53.02% |
| 2020-12-31 | 69.37% |
| 2020-09-30 | 71.73% |
| 2020-06-30 | 67.45% |
| 2020-03-31 | 22.21% |
| 2019-12-31 | 50.70% |
| 2019-09-30 | 2.60% |
| 2019-06-30 | 26.11% |
| 2019-03-31 | 45.59% |
| 2018-12-31 | 40.04% |
| 2018-09-30 | 34.92% |
| 2018-06-30 | 31.21% |
| 2018-03-31 | 42.29% |
| 2017-12-31 | 58.93% |
| 2017-09-30 | 81.26% |
| 2017-06-30 | 97.24% |
| 2017-03-31 | 98.04% |
| 2016-12-31 | 47.71% |
| 2016-09-30 | 80.42% |
| 2016-06-30 | 64.21% |
| 2016-03-31 | 51.85% |
| 2015-12-31 | 35.55% |
| 2015-09-30 | 52.83% |
| 2015-06-30 | 73.14% |
| 2015-03-31 | 45.02% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
